Literature DB >> 24772665

Biomarkers of liver fibrosis.

Ki Tae Suk, Dae Yong Kim, Kyoung Min Sohn, Dong Joon Kim.   

Abstract

Liver fibrosis is the final common pathway for almost all causes of chronic liver injury. Liver fibrosis is now known to be a dynamic process having significant potential for resolution. Therefore, fibrosis prediction is an essential part of the assessment and management of patients with chronic liver disease. As such, there is strong demand for reliable liver biomarkers that provide insight into disease etiology, diagnosis, therapy, and prognosis in lieu of more invasive approaches such as liver biopsy. Current diagnostic strategies range from use of serum biomarkers to more advanced imaging techniques including transient elastography and magnetic resonance imaging. In addition to these modalities, there are other approaches including the use of novel, but yet to be validated, biomarkers. In this chapter, we discuss the biomarkers of liver fibrosis including the use of invasive and noninvasive biomarkers and disease-specific biomarkers in various chronic liver diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24772665     DOI: 10.1016/b978-0-12-800096-0.00002-0

Source DB:  PubMed          Journal:  Adv Clin Chem        ISSN: 0065-2423            Impact factor:   5.394


  2 in total

Review 1.  Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement.

Authors:  Ki Tae Suk; Dong Joon Kim
Journal:  World J Hepatol       Date:  2015-03-27

2.  Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease.

Authors:  Qiu-Zan Zhang; Ying-Li Liu; Yan-Rong Wang; Li-Na Fu; Jing Zhang; Xiu-Ru Wang; Bang-Mao Wang
Journal:  Exp Ther Med       Date:  2017-07-19       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.